<SEC-DOCUMENT>0001104659-16-160502.txt : 20161205
<SEC-HEADER>0001104659-16-160502.hdr.sgml : 20161205
<ACCEPTANCE-DATETIME>20161205074833
ACCESSION NUMBER:		0001104659-16-160502
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20161205
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161205
DATE AS OF CHANGE:		20161205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adaptimmune Therapeutics PLC
		CENTRAL INDEX KEY:			0001621227
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37368
		FILM NUMBER:		162032675

	BUSINESS ADDRESS:	
		STREET 1:		101 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY
		BUSINESS PHONE:		44 1235 430000

	MAIL ADDRESS:	
		STREET 1:		101 PARK DRIVE
		STREET 2:		MILTON PARK
		CITY:			ABINGDON, OXFORDSHIRE
		STATE:			X0
		ZIP:			OX14 4RY

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Adaptimmune Ltd
		DATE OF NAME CHANGE:	20141001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a16-22570_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES <br> SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Current Report</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):<b> December&nbsp;5, 2016</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ADAPTIMMUNE THERAPEUTICS PLC</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">England   and Wales</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-37368</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not   Applicable</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other   jurisdiction of<br>   incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">101 Park Drive, Milton Park</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Abingdon, Oxfordshire OX14 4RY</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">United Kingdom</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices, including zip code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(44) 1235 430000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109562\16-22570-1\task8193006\22570-1-ba.htm',USER='109562',CD='Dec  3 01:28 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item&nbsp;7.01 </font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Other Events.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><font style="font-size:10.0pt;">On December&nbsp;5, 2016, Adaptimmune Therapeutics plc (the &#147;Company&#148;) issued a press release a</font>nnouncing that it has initiated a study of its NY-ESO SPEAR&#153; T-cells in myxoid/round cell liposarcoma (MRCLS). Patient screening is underway, and </font>the results from this study in up to 15 patients will inform a potential future registration trial. The initiation of screening in this study meets a milestone set forth in the Company&#146;s strategic collaboration agreement with GlaxoSmithKline plc (LSE/NYSE: GSK).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The press release is furnished as Exhibit&nbsp;99.1 to this Current Report on Form&nbsp;8-K and is incorporated by reference herein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The information in Item&nbsp;7.01 of this Form&nbsp;8-K (including Exhibit&nbsp;99.1) shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered &#147;filed&#148; or incorporated by reference therein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01</font></b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <b>Financial Statements and Exhibits.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)&nbsp; Exhibits.&#160; The following exhibit is furnished as part of this Report on Form&nbsp;8-K:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:.5in;">
<tr>
<td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="89%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:89.3%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.02%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.68%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="89%" valign="top" style="padding:0in 0in 0in 0in;width:89.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release dated   December&nbsp;5, 2016.</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_011039_9919"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109562\16-22570-1\task8193006\22570-1-ba.htm',USER='109562',CD='Dec  3 01:28 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ADAPTIMMUNE   THERAPEUTICS PLC</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt .25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: December&nbsp;5,   2016 </font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" colspan="2" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.58%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Name:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="top" style="padding:0in 0in 0in 0in;width:6.42%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Title:</font></p>    </td>
<td width="39%" valign="top" style="padding:0in 0in 0in 0in;width:39.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Corporate Secretary</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_011120_7056"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109562\16-22570-1\task8193006\22570-1-ba.htm',USER='109562',CD='Dec  3 01:28 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;Index</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="87%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:87.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Exhibit</font></b></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="10%" valign="top" style="padding:0in 0in 0in 0in;width:10.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="87%" valign="top" style="padding:0in 0in 0in 0in;width:87.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release dated   December&nbsp;5, 2016</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">4<a name="PB_4_011141_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\109562\16-22570-1\task8193006\22570-1-ba.htm',USER='109562',CD='Dec  3 01:28 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a16-22570_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;99.1</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="342" height="75" src="g225701mmi001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PHILADELPHIA, Pa. and OXFORD, UK., December&nbsp;5, 2016 &#151; Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY-ESO SPEAR&#153; T-cells in myxoid/round cell liposarcoma (MRCLS). Patient screening is underway, and </font>the results from this study in up to 15 patients will inform a potential future registration trial. The initiation of screening in this study meets a milestone set forth in the Company&#146;s strategic collaboration agreement with GlaxoSmithKline plc (LSE/NYSE: GSK).</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This is an open-label pilot study in patients to assess preliminary safety and efficacy in this new indication. Initially, 10 patients will be enrolled. If further characterization of the treatment is required, up to 5 additional patients may be enrolled. Eligible patients will be HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 with advanced (metastatic or inoperable) high grade MRCLS whose tumor shows positive NY-ESO-1 expression defined as <u>&gt;</u>30 percent of cells that are 2+ or 3+ by immunohistochemistry. Patients will receive preconditioning with fludarabine and cyclophosphamide at the same dose that is being used in Cohort&nbsp;4 of the Company&#146;s ongoing synovial sarcoma study.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About MRCLS</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Soft tissue sarcomas can develop from tissues like fat, muscle, nerves, fibrous tissues, blood vessels, or deep skin tissues. There are approximately 50 types of soft tissue sarcomas, including MRCLS. Myxoid/round cell liposarcoma is associated with specific chromosomal translocations and represents about 30 to 35 percent of liposarcomas and 5 to 10 percent of all adult soft tissue sarcomas. Myxoid/round cell liposarcoma commonly presents at an age ranging from 35 to 55 years.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Adaptimmune</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform. Established in 2008, the Company aims to utilize the body&#146;s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune&#146;s lead program is a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. Adaptimmune has a strategic collaboration and licensing agreement with GlaxoSmithKline for the development and commercialization of the NY-ESO TCR program. In addition, Adaptimmune has a number of proprietary programs. </font>These include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens, which both have open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance targeted for 2017. The Company has identified over 25 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 250 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109557\16-22570-1\task8192989\22570-1-mm.htm',USER='109557',CD='Dec  3 01:15 2016' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This release contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). </font>These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form&nbsp;10-Q filed with the Securities and Exchange Commission (SEC) on November&nbsp;10, 2016, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adaptimmune Contacts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Investor Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Will Roberts</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T:&#160; (215) 825-9306</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: will.roberts@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Juli P. Miller, Ph.D.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: (215) 825-9310</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: juli.miller@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Media Relations</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Margaret Henry</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">T: +44 (0)1235 430036</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile: +44 (0)7710 304249</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">E: margaret.henry@adaptimmune.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109557\16-22570-1\task8192989\22570-1-mm.htm',USER='109557',CD='Dec  3 01:15 2016' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g225701mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g225701mmi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !+ 58# 2(  A$! Q$!_\0
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,N;G?5@**6BF8G__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
